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A B S T R A C T
Purpose and methods: Migraine, with or without aura, affects from 10% to 14% of the population, and is as
such one of the most common headache disorders. A uniﬁed hypothesis for the physiopathology of
migraine and its relationship with epileptic migraine and migralepsy has yet to be formulated.
Trigemino-vascular system (TVS) activation is believed to play a crucial role in the ‘‘pain phase’’ in
migraine; cortical spreading depression (CSD) is considered to be the primary cause of TVS activation.
On the basis of data in the literature, I would like to stress that TVS activation may originate at
different cortical and subcortical levels. For example, as recently reported, an epileptic focus, originating
and propagating along cortical non-eloquent/silent areas, through CSD, rarely causes TVS activationwith
migraine as the sole ictal epileptic manifestation.
Results and conclusion: Themultiple considerations that arise from this hypothesis, including the under-
diagnosed ictal epileptic headache, are discussed; EEG (ictal and inter-ictal) recording with intermittent
photic stimulation (IPS), according to the standardized international protocol, is strongly recommended
in selected migraine populations.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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theory
Functional neuroimaging1 and neurophysiological studies2–7
have revealed that primary headaches (both tension-type and
migraine type) may be characterised by different activation
patterns of the central and peripheral pain modulatory structures,
most of which have been identiﬁed by numerous authors in recent
decades as possible sites of speciﬁc impairment (functional or
structural) involved in the physiopathology of headache.2–11
Among these, studies on the role of cortical spreading depression
(CSD) and trigemino-vascular system (TVS) activation in the* Tel.: +39 06 49979311; fax: +39 06 49979312.
E-mail address: pasquale.parisi@uniroma1.it.
1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.01.010physiopathology of migraine have attracted the attention of the
leading experts in this ﬁeld.12–13
The discovery of CSD represents a perfect example of so-called
‘‘serendipity phenomena’’. In other words, it illustrates how an
unexpected, chance observation, if made by an alert experimenter,
canopenanew,major area of investigation.14–15 In animals, CSD can
be triggered by focal stimulation (electrical, mechanical, with high
extracellular K+or glutamate, persistent intracellular sodium inﬂux,
inhibition of the Na+–K+ ATPase pump), as well as by several other
stimuli of the cerebral cortex, more readily in the occipital region
than in other regions.14–16 CSD is characterized by a slowly
propagating wave (2–6 mm/min) of sustained strong neuronal
depolarization that generates transient (in the order of seconds),
intense spike activity as it progresses into the tissue, followed by
neural suppression which may last for minutes. CSD represents a
regenerative ‘‘all-or-none’’ event (a neurophysiologic characteristic
shared with the ‘‘membrane depolarization’’ underlying a focalvier Ltd. All rights reserved.
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fashion in brain tissue. The depolarization phase is associated with
an increase in regional cerebral bloodﬂow(rCBF),whereas thephase
of reduced neural activity is associated with a reduction in rCBF.
Opinions are divided as to whether CSD plays a physiological17 or a
neuro-protective role.18
Moskowitz and co-workers have, since 1993, been making a
major contribution, by means of experimental data12,13,19 and
functional neuroradiological investigations in humans,1 to the
search for possible correlations between CSD onset and TVS
activation; TVS activation is considered to represent ‘‘the common
ﬁnal pathway’’, which consists of a cascade release of numerous
inﬂammatory molecules (sterile inﬂammation) and neurotrans-
mitters that are a ‘‘sine qua non’’ condition resulting in pain during
the attacks. CSD is considered to be the primary cause for TVS
activation. These studies by Moskowitz and co-workers have
strongly contributed to the formulation of the ‘‘trigemino-vascular
theory’’, which has become themost widely accepted theory in the
physiopathology of migraine. The correlation between CSD and
migraine with aura (MA) was demonstrated ﬁrst12,13,19; more
recently, imaging studies in patients suffering from migraine
without aura (MoA) have also pointed to the presence of CSD in
silent areas as an underlying mechanism.20–23
It should be borne inmind that CSD is not a phenomenon that is
‘‘strictly’’ peculiar to the cortical structures. Cortical and sub-
cortical areas appear to be hierarchically divided according to how
likely they are to develop CSD,14,24 though the occipital lobe
appears to be the area most likely to be affected.
2. Link between CSD and cortical focal paroxysmal discharge
(neurophysiopathologic and genetic link level)
Worthy of attention is an old ﬁnding in the literature regarding
the properties and the critical role that the Na+–K+ ATPase pump
plays in the regulation of both seizure onset, by acting on
membrane depolarization (due to inhibitory potential post-
synaptic modulation), and CSD, by modifying the local K+
concentration. This old experimental ﬁnding linked both seizure
and CSD onset to the ability of the Na–K pump to regulate K+
extracellular concentrations.25 Intriguingly, thirteen years later,
this experimental ﬁnding was conﬁrmed in humans by a novel
mutation in the Na+–K+ ATPase pump associated with two
phenotypically different pictures: familial hemiplegic migraine
(FHM) and benign familial infantile convulsions (BFIC).26 More-
over, a monogenic defect in familial occipital lobe epilepsy
associated with MA was reported.27
An important role in the phenomenon linking the onset of CSD
and cortical focal epileptic discharges might be played by
complementary mechanisms responsible for ionic diffusion in
both these events (i.e. epileptic depolarization and CSD onset). The
velocity of ionic diffusion across neuronal cytoplasmic bridges (gap
junctions) is different from that through interstitial spaces, though
both converge in the membrane excitability modulation. Synchro-
nization in CSD has been hypothesized to be caused by the non-
synaptic interaction between neuronesmediated by the excitatory
neurotransmitter glutamate or through ‘‘gap junctional’’ interac-
tions.28 Moreover, the previously reported gap junction properties
in the modulation of CSD onset29 and spreading14,29 as well as the
anticonvulsant properties of gap junction blockers30 have been
documented. Yet other data highlight the role of gap junctions in
synchronizing the human neocortical network, which in turn
increases epileptiform activity.31
More recently,32 CSD has been reported to facilitate synaptic
excitability in human neocortical tissues, thus contributing to the
hyperexcitability of neocortical tissues in patients suffering from
migraine. Moreover, calcium-sensitive current can promote bothseizure-like discharges and CSD in a model neuron.33 Data thus
conﬁrm that CSD (migraine) and cortical focal discharges
(seizures) facilitate each other.
Lastly, it is highly interesting that these data are supported,
going back into the past, by Leao himself, who described, while
studying ‘‘experimental epilepsy’’,34 CSD onset due to the
propagation of electrically provoked seizure discharges in the
cerebral cortex and, in the same article, the similarity in the ways
in which CSD and seizures propagate.
3. Link between migraine and epilepsy (clinical link level)
The association between headache/migraine and seizures is a
widespread, well-known event. Headache/migraine are associated
with seizure occurrence in 34–58% of epileptic patients, 60% of
whom have a peri-ictal headache alone, i.e. headache/migraine in
such subjects are always temporally related to seizures. According
to the international criteria,35 about 37% of headaches are tension-
type while about 55% are migraine (75% MoA and 15% MA)36–39;
the rate of peri-ictal headache reported in the literature (34–58%)
is very similar in both past36 and more recent37–39 studies. The
temporal relationship between migraine/headache and seizures
allows us to subdivide headaches as follows36–39: 5–27% are only
pre-ictal, 2.2% are ictal,38 30–70% are only post-ictal, while 7–27%
are both pre-ictal and post-ictal.
Problems have arisen in international criteria regarding the
deﬁnition of the rare condition in which migraine (even more
rarely, tension-type headache) may be the sole semeiologic
manifestation of the epileptic seizure.
Our group recently described40 a 14-year-old girl who had a
photosensitive occipital epileptic seizure followed by a status
migrainosus that lasted 3 days. An EEG revealed occipital status
epilepticus during her migraine attack; intravenous administra-
tion of diazepam, under continuous EEG recording, suppressed
both the epileptiform discharges and headache complaints. Three
days later, we evoked visual aura and migraine in this patient
during an EEG recording by means of intermittent photic
stimulation (IPS).40 It is particularly intriguing that IPS can trigger
both migraine attacks and epileptic seizures. On the basis of our
observations, we also recently suggested that the diagnostic
criteria for ‘‘hemicrania epileptica’’ in Migraine and Epilepsy
International Classiﬁcations35,41 be revised, and that the impor-
tance of EEG recordings with standardized IPS be stressed.42,43 We
also proposed the term ‘‘ictal epileptic headache’’ for ‘‘migraine/
headache’’ as the sole semeiologic epileptic ictal phenomena.43
Another noteworthy point is the existence of migraine attacks
that occur separately in-between epileptic seizures (interictal
migraine), which may (rarely) represent the sole ictal epileptic
manifestation in subjects previously diagnosed as epileptic and
(even more rarely) in patients in whom epilepsy was not
diagnosed. In this regard, the role of EEG recording should not
be underestimated.
4. Final hypothesis, suggestions and future directions
The ‘‘sine qua non’’ condition for headache is TVS activation,
which is believed to be the only neural pathway able to induce
migraine (with or without aura).
In the central nervous system, there appears to be a hierarchical
organization based on ‘‘neuronal networks’’ (cortical and sub-
cortical) that may be more or less prone to CSD (migraine) and
epileptic focal discharges (seizures). Onset and propagation are
triggered when these neurophysiological events reach a certain
threshold (‘‘all or-none events’’), which is lower for the onset of
CSD than that of the seizure. Once the cortical event is started, the
way in which it spreads depends on the size of the onset zone, its
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all of which may vary within the same patient at different times.
The onset of CSD and of the epileptic seizure may facilitate each
other.14,16,31,32 The underlying neurophysiological causes may be
the same, with the two phenomena displaying the ‘‘all-or-none’’
(as mentioned above) characteristic, which may be triggered by
more than one pathway converging upon the same destination
(depolarization and hypersynchronization). The triggering causes,
which may be environmental or individual (whether genetically
determined or not), result in a ﬂow of ions that mediate CSD above
all through neuronal (and probably glial) cytoplasmic bridges
(intracellular gap-junctions) rather than through interstitial
spaces, as usually happens in the spreading of epileptic
seizures.14,44 Furthermore, the threshold required for the onset
of CSD is likely to be lower than that required for the epileptic
seizure. In other words, I believe that the onset of the epileptic
seizure facilitates the onset of CSD to a greater degree than the
onset of CSD facilitates the onset of the epileptic seizure. Thus, as
epidemiologic studies in the literature suggest,36–39,45,46 in the
clinical context we are more likely to observe epileptic patients
with ‘‘comorbid’’ (peri-ictal and interictal) migraine than migraine
subjects with ‘‘comorbid’’ epilepsy.
4.1. Why is migraine rarely, and not usually, the sole ictal epileptic
phenomenon?
Migraine without aura is thought to be the result of a CSD that
starts and propagates from silent cortical areas following TVS
activation (pain phase), without any additional signs/symptoms.
Similarly, an epileptic seizure, whose onset and propagation occur
along silent/non-eloquent cortical areas, may activate the TVS,
which results in a migraine attack without any additional epileptic
signs/symptoms.40,42–44 The latter condition is understandably
very rare, it being statistically highly unlikely that this type of
event might occur by chance. This observation is supported by the
fact that peri-ictal headaches associated with other signs/
symptoms during an epileptic seizure are very common (34–
58%),36–39,45,46 which in turn conﬁrms that the threshold for
migraine onset is lower than that of seizure onset. In this regard, a
‘migraleptic’ event, i.e. a migraine attack followed by epileptic
seizures, is also very rare because the threshold required for
seizure onset and propagation is higher.
Therefore, migraine (with or without aura), along with all other
headache types (the literature on other headache disorders is
unfortunately more limited), is highly unlikely to be an epileptic
event, but rather the result of cortical or subcortical events that
activate the TVS. These eventsmight consist of CSD or ‘‘subcortical’’
spreading depression, or be caused by environmental, individual or
genetic noxae, which cause an impairment that ‘‘interferes’’ with
the very complex polysynaptic and polymolecular cascade at the
subcortical level in the TVS networks.
The last, though not the least, of the considerations that arise
from this hypothesis concerns the under-diagnosed ictal epileptic
headache which, while rare, is a strongly debated topic that
deserves some considerations. Indeed, the potential implications
that arise from this topic include44: (a) a revision of the headache/
migraine diagnostic criteria in order to include headache/migraine
criterion as a possible sole ictal epileptic manifestation42; (b) the
careful follow-up of patients with headache/migraine as a residual
feature, taking into account a revised concept of ‘‘complete seizure
control’’ to avoid mistakes due to the inopportune withdrawal of
antiepileptic treatment.42,44 In addition, it should be borne inmind
that headache may be associated with ictal-sensory and motor
features more frequently than the literature suggests; indeed, this
association might be strongly underestimated owing to impaired
consciousness during complex partial seizures with or withoutsecondary generalization. In this respect, an ictal EEG (during the
migraine attack) should be recommended in every migraine
patient, even in subjects who are not known to be epileptic. During
an interictal EEG (or video-EEG) recording, particular attention
should always be paid to the ictal onset of the clinical-EEG ﬁndings
(and not the EEG abnormalities alone, which are relatively
common) during IPS, performed according to the standardized
international protocol.47 As regards the criteria for the selection of
patients in whom amore thorough EEG investigation is warranted,
the abrupt onset of headache, a short attack duration (i.e. lasting
minutes) and the migraine-like characteristics of the attacks (as
opposed to the tension-type ones) may be a good starting point.
Another intriguing issue is the difference between the clinical
picture of adult and that of childhood in both epilepsy and
headache. Autonomic manifestations are more prevalent in the
childhood headache clinical picture, as well it is observed in most
early benign focal idiopathic epileptic childhood syndromes, such
as the well-known Panayiotopoulos syndrome (PS). In this regard,
our group documented a child affected by PS48 whose interictal
migraine attacks (in-between the nocturnal seizures) completely
remitted (as did the seizures) after the administration of antic-
onvulsant therapy.
From the therapeutic point of view, the anticipation of the
cortical event (CSD) that induces secondary TVS activation
probably explains why AED treatment is more effective in the
prophylaxis phase than in the pain phase (migraine attack). In
order to ‘‘interfere’’ with this very complex polysynaptic and
polymolecular cascade, several cortical and subcortical levels must
be acted upon; the model proposed here (multiple different
cortical and subcortical levels underlying the onset of migraine
attacks) is supported in the literature by a number of molecules
with different pharmacological properties that have proved
(clinically and experimentally)8,19,49–55 to play a therapeutic role
in migraine.
Future research is warranted to identify the various levels of the
cortico-subcortical polysynaptic molecular cascade, which will
hopefully providemigraine (whether epileptic or not) therapywith
speciﬁc pharmacological properties tailored for individual
patients.
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